Latest Regulatory Approvals News

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Spheria Emerging Companies Limited has updated its dividend distribution approach, opting to use cash dividends to buy shares on-market due to the share price falling below its post-tax NTA per share on the ex-dividend date.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Anax Metals has locked in a $3.3 million convertible note investment from Mineral Development Partners, with conditional commitments for up to $100 million to advance the Whim Creek Project and establish a Pilbara base metals hub.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

MinRex Resources has secured all approvals to commence a fully funded drilling program targeting high-priority copper-gold deposits at the Fraser Range Project in Western Australia, aiming to unlock significant exploration potential.

Stellar Resources reports strong high-grade tin intercepts at Queen Hill, underpinning potential resource upgrades and advancing the Heemskirk Tin Project towards development.

AVJennings reported a 25% rise in Q3 FY25 contract signings and a 26% increase in settlements, while progressing an acquisition scheme that could reshape its future.

Global uranium enrichment leader Urenco has agreed to invest A$5 million in Australian technology developer Ubaryon, forming a strategic partnership that validates and accelerates a novel uranium enrichment process.

Neurizon Therapeutics has announced the successful completion of its Open-Label Extension study for NUZ-001 in ALS, revealing significant survival benefits and strong tolerability. The company is on track to release top-line results in Q3 2025 and advance to a pivotal Phase 2/3 trial.

Adelong Gold is set to begin a significant diamond drilling campaign at its Apollo Gold Project in Victoria, aiming to extend high-grade gold mineralisation in the Dig Fault Zone. The program follows all approvals and a contract with GMP Exploration Drilling, with results expected to shape future resource modelling.

Gold Road Resources has entered a definitive agreement for acquisition by Gold Fields Limited, offering shareholders a compelling 43% premium and a special dividend. The scheme awaits shareholder and court approval, targeting completion by October 2025.